Header
For Healthcare Professionals
jardiance-met-overview

In T2D patients with high baseline HbA1C

Jardiance Met® delivered powerful HbA1c reduction1

delivered powerful
delivered powerful

For your patients with type 2 diabetes

Jardiance Met® combines the benefits of Empagliflozin with metformin in one convenient pill

benefits of Empagliflozin
benefits of Empagliflozin

Empagliflozin and Jardiance Met® are not indicated for weight loss or reduction of blood pressure.2,4

  1. Hadjadj S, Rosenstock J, Meinicke T, et al. Initial Combination of Empagliflozin and Metformin in Patients with Type 2 Diabetes. Diabetes Care. 2016;39(10):1718-1728.

  2. Jardiance Met® India prescribing information dated April 2025.

  3. Zinman B, Wanner C, Lachin J, et al; EMPA-REG OUTCOME® Investigators. Empagliflozin, cardiovascular outcomes and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128. (EMPA-REG OUTCOME® results and the publication’s Supplementary Appendix for certain baseline characteristics).

  4. Patorno E, Pawar A, Franklin J, et al. Empagliflozin and the risk of heart failure hospitalization in routine clinical care: a first analysis from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study. Circulation. 2019;139(25):2822-2830.

  • †
    In adult patients with insufficiently controlled type 2 diabetes and CAD, PAD, or a history of MI or stroke. The 38% RRR in CV death was achieved in the overall EMPA‐REG OUTCOME® population for the duration of the trial (HR=0.62; 95% CI: 0.49, 0.77; p<0.001).2,3
  • BID,
     twice a day; CV, cardiovascular; HbA1c, hemoglobin A1c; SE, standard error; T2D, type 2 diabetes.